EGFR and breast cancer: Perhaps the most prominent oncodriver investigated in the context of breast cancer is human epidermal growth factor receptor 2/receptor tyrosine-protein kinase erbB-2 (HER2/Erbb2), and other members of the ERBB family of receptors, namely EGFR/HER1, HER3 and HER4, have been established as potent oncodrivers in breast cancer, along with lung, ovarian, gastric and bladder carcinoma (140–142).